AL9-32279-23032
2 vaccinations
1 coded response
19 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 430 / OH
- Registered
- 2021-09-14
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-09-14
Registered in v-safe
-
2021-09-14
Dose 1 — Pfizer-BioNTech
- 2021-09-14
- 2021-09-17
- 2021-09-18
- 2021-09-20
- 2021-09-21
- 2021-09-30
-
2021-10-05
Dose 2 — Pfizer-BioNTech
- 2021-10-05
- 2021-10-07
- 2021-10-09
- 2021-10-10
- 2021-10-11
- 2021-10-12
- 2021-10-19
- 2021-10-26
- 2021-11-02
- 2021-11-09
- 2021-11-16
-
2022-01-06
Survey response — 3 months, dose 2MedDRA: Ageusia, Anosmia, Cough, Headache, Nasal congestion — Feeling: Good · Be unable to work or attend schoolFree text: Headache, nasal congestion, cough and loss of taste and smellMedDRA releases: 2024-11 · check-in free text available
- 2022-04-05
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-09-14 | Pfizer-BioNTech | No |
| 2 | 2021-10-05 | Pfizer-BioNTech | No |
Free text
Release 10 — 3 months, dose 2
Symptoms: Headache, nasal congestion, cough and loss of taste and smell
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Nasal congestion | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release